公开(公告)号：US09133206B2

公开(公告)日：2015-09-15

申请号：US14179163

申请日：2014-02-12

Applicant: AbbVie Inc.

Inventor： William H. Bunnelle ,  Marc Scanio ,  Jason T. Brewer ,  Ying Wang ,  Irini Akritopoulou-Zanze

IPC: C07D487/12 ,  C07D491/00 ,  A61K31/55 ,  C07D487/14 ,  C07D487/04

CPC classification number: C07D487/04 ,  C07D487/14

Abstract: The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) wherein R1, R2, R3, R4, X1, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及式（I）的苯并二氮杂和吡啶并二氮杂衍生物，其中R 1，R 2，R 3，R 4，X 1，Y 1，Y 2和Y 3如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：US20140163014A1

公开(公告)日：2014-06-12

申请号：US14179163

申请日：2014-02-12

Applicant: AbbVie Inc.

Inventor： William H. Bunnelle ,  Marc Scanio ,  Jason T. Brewer ,  Ying Wang ,  Irini Akritopoulou-Zanze

IPC: C07D487/14 ,  C07D487/04

CPC classification number: C07D487/04 ,  C07D487/14

Abstract: The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) wherein R1, R2, R3, R4, X1, Y1, Y2, and Y3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及式（I）的苯并二氮杂和吡啶并二氮杂衍生物，其中R 1，R 2，R 3，R 4，X 1，Y 1，Y 2和Y 3如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：US20180024144A1

公开(公告)日：2018-01-25

申请号：US15454313

申请日：2017-03-09

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Chih-hung Lee ,  Tao Li ,  Gregory Gfesser ,  Kathleen Mortell ,  Ramin Faghih ,  Diana L. Schmidt ,  Kevin Sippy ,  William H. Bunnelle ,  Marc Scanio ,  Lei Shi ,  Murali Gopalakrishnan ,  Diana L. Donnelly-Roberts ,  Min Hu

IPC: G01N33/68 ,  G01N33/50 ,  C07D471/18 ,  C07D487/10

CPC classification number: G01N33/6896 ,  C07D471/18 ,  C07D487/10 ,  G01N33/5058 ,  G01N2800/2814 ,  G01N2800/30

Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：US20160376240A1

公开(公告)日：2016-12-29

申请号：US15112870

申请日：2015-01-16

Applicant: ABBVIE INC.

Inventor： William Bunnelle ,  Marlon Cowart ,  Irene Drizin ,  John Robert Koenig ,  Marina Pliushchev ,  Marc Scanio

IPC: C07D231/56 ,  C07D405/14 ,  C07D417/14 ,  C07D487/10 ,  C07D403/12 ,  C07D471/04 ,  C07D413/10 ,  C07D401/10 ,  C07D405/12 ,  C07D401/12

CPC classification number: C07D231/56 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D413/10 ,  C07D417/14 ,  C07D471/04 ,  C07D487/10

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Abstract translation: 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2，R3，R4，R5，R6和X如说明书中所定义，可用于治疗病症或障碍 由Tropomysin受体激酶（Trk）改变或改善。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。

公开(公告)号：US20150353550A1

公开(公告)日：2015-12-10

申请号：US14715330

申请日：2015-05-18

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Chih-Hung Lee ,  Tao Li ,  Gregory A. Gfesser ,  Kathleen H. Mortell ,  Ramin Faghih ,  Diana L. Nersesian ,  Kevin B. Sippy ,  William H. Bunnelle ,  Marc Scanio ,  Lei Shi ,  Murali Gopalakrishnan ,  Diana L. Donnelly-Roberts ,  Min Hu

IPC: C07D471/18

CPC classification number: G01N33/5058 ,  C07D471/18 ,  C07D487/10 ,  C07D487/18 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/30

Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

Abstract translation: 本申请涉及式（I），（II），（III），（IV），（V）或（VI）的吲哚和二氢吲哚衍生物，其中a，R1，R2，R3，R4，R5， V，W，X，Y和Z如说明书中所定义。 本申请还涉及包含这些化合物的组合物，以及使用这些化合物和组合物治疗疾病状况的方法，以及鉴定这些化合物的方法。

公开(公告)号：US20150158867A1

公开(公告)日：2015-06-11

申请号：US14624517

申请日：2015-02-17

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Diana L. Nersesian ,  Kevin B. Sippy ,  Jianguo Ji ,  Tao Li ,  Marc Scanio ,  Lei Shi ,  Chih-Hung Lee ,  William H. Bunnelle ,  Geoff G.Z. Zhang ,  Paul J. Brackemeyer ,  Shuang Chen ,  Rodger F. Henry

IPC: C07D471/18 ,  A61K31/439 ,  A61K31/501 ,  A61K31/444 ,  C07C309/29 ,  A61K31/095

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Abstract translation: 本发明涉及作为氮杂金刚烷衍生物的化合物，特别是醚取代或胺取代的氮杂金刚烷衍生物及其盐和前体药物，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法以及在此过程中获得的中间体 。

公开(公告)号：US08987453B2

公开(公告)日：2015-03-24

申请号：US13653192

申请日：2012-10-16

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Diana L. Nersesian ,  Kevin B. Sippy ,  Jianguo Ji ,  Tao Li ,  Marc Scanio ,  Lei Shi ,  Chih-Hung Lee ,  William H. Bunnelle ,  Geoff G. Z. Zhang ,  Paul J. Brackemeyer ,  Shuang Chen ,  Rodger F. Henry

IPC: C07D471/18 ,  A61K45/06 ,  A61K31/444 ,  C07D471/08 ,  C07F5/02 ,  A61K31/439 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

Abstract translation: 本发明涉及作为氮杂金刚烷衍生物的化合物，特别是醚取代或胺取代的氮杂金刚烷衍生物及其盐和前体药物，包含这些化合物的组合物，使用这些化合物和组合物的方法，制备这些化合物的方法以及在此过程中获得的中间体 。

公开(公告)号：US20130096132A1

公开(公告)日：2013-04-18

申请号：US13653192

申请日：2012-10-16

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Diana L. Nersesian ,  Kevin B. Sippy ,  Jianguo Ji ,  Tao Li ,  Marc Scanio ,  Lei Shi ,  Chih-Hung Lee ,  William H. Bunnelle ,  Geoff G.Z. Zhang ,  Paul J. Brackemeyer ,  Shuang Chen ,  Rodger F. Henry

IPC: C07D471/18 ,  A61K45/06 ,  A61K31/501 ,  A61K31/496 ,  A61K31/506 ,  A61K31/497 ,  A61K31/439 ,  A61K31/444

CPC classification number: C07D471/18 ,  A61K31/095 ,  A61K31/439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  C07C309/29 ,  C07D451/14 ,  C07D471/08 ,  C07F5/022

Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.

公开(公告)号：US09983218B2

公开(公告)日：2018-05-29

申请号：US15454313

申请日：2017-03-09

Applicant: AbbVie Inc.

Inventor： Michael R. Schrimpf ,  Chih-hung Lee ,  Tao Li ,  Gregory Gfesser ,  Kathleen Mortell ,  Ramin Faghih ,  Diana L. Schmidt ,  Kevin Sippy ,  William H. Bunnelle ,  Marc Scanio ,  Lei Shi ,  Murali Gopalakrishnan ,  Diana L. Donnelly-Roberts ,  Min Hu

IPC: C07D471/18 ,  G01N33/68 ,  C07D487/10 ,  G01N33/50

CPC classification number: G01N33/6896 ,  C07D471/18 ,  C07D487/10 ,  G01N33/5058 ,  G01N2800/2814 ,  G01N2800/30

Abstract: The present application relates to indole and indoline derivatives of formula (I), (II), (III), (IV), (V), or (VI) wherein a, R1, R2, R3, R4, R5, U, V, W, X, Y, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

公开(公告)号：US09783527B2

公开(公告)日：2017-10-10

申请号：US14854433

申请日：2015-09-15

Applicant: AbbVie Inc.

Inventor： Jerome F. Daanen ,  David A. DeGoey ,  Jennifer M. Frost ,  John R. Koenig ,  Steve Latshaw ,  Mark Matulenko ,  Marc Scanio ,  Lei Shi ,  William H. Bunnelle

IPC: A61K31/497 ,  A61K31/4178 ,  A61K31/4985 ,  C07D403/04 ,  C07D403/14 ,  C07D487/14 ,  C07D491/08 ,  C07D413/14 ,  C07D405/14 ,  C07D417/14 ,  C07D401/14

CPC classification number: C07D403/14 ,  A61K31/4178 ,  A61K31/497 ,  A61K31/4985 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/14 ,  C07D491/08

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, R1 and R2 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.